Windjammer Capital Investors (“Windjammer”), a notable private equity investment firm, has announced its acquisition of Bio X Cell, LLC (“BXC”), marking a significant move in the biotech industry. This acquisition, completed on November 6, represents Windjammer’s strategic investment in a leading producer of monoclonal antibodies, vital for pre-clinical research applications.

Founded by Dr. Klaus Lubbe in 1997, Bio X Cell has transitioned from a contract manufacturer of antibodies to a premier provider of “off-the-shelf”, ultra-pure, low endotoxin monoclonal antibodies. This evolution positions BXC as the only pure-play in vivo monoclonal antibodies manufacturer of scale.

Windjammer and Bio X Cell: A Synergistic Partnership

Craig Majernik, Managing Director at Windjammer, expressed excitement about the partnership, recognizing Bio X Cell as the ‘gold standard’ in RUO in vivo antibodies. The acquisition aligns with Windjammer’s downstream expansion strategy and taps into the growing life science tools industry. Majernik sees a substantial opportunity to accelerate growth by building on BXC’s strong product foundation and expanding its market reach through strategic acquisitions.

Bio X Cell’s extensive portfolio includes over 400 functional grade antibodies used by more than 1,500 academic, government, and commercial customers across various research fields. These antibodies have been cited in over 20,000 research publications, underlining BXC’s impact in the research community. The company’s global reach extends to over 50 countries, including the Americas, Europe, and Asia.

A Mission-Driven Approach to Scientific Innovation

Klaus Lubbe, founder and CEO of Bio X Cell, emphasized the importance of quality products and exceptional customer service in advancing scientific discovery. He recognized Windjammer’s appreciation of BXC’s company culture, which has been a significant factor in its success. Lubbe is optimistic about the future of BXC under this new partnership.

Greg Bondick, Managing Principal at Windjammer, remarked on BXC’s niche market leadership and its alignment with Windjammer’s investment strategy, which focuses on mission-critical, low cost-to-value product offerings.

Future Prospects and Integration

The integration of Bio X Cell into Windjammer’s portfolio begins immediately, with a focus on enhancing both companies’ capabilities to serve the dynamic needs of the biotech industry. This strategic acquisition is set to open new avenues for innovation and market presence in the rapidly evolving biotechnology sector.

  Bio X Cell, Craig Majernik, Dr. Klaus Lubbe, Greg Bondick, Pharma acquisition news, Windjammer Capital Investors